How to handle the delayed or missed dose of rivaroxaban in patients with non-valvular atrial fibrillation: model-informed remedial dosing
- 28 July 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Expert Review of Clinical Pharmacology
- Vol. 14 (9), 1153-1163
- https://doi.org/10.1080/17512433.2021.1937126
Abstract
Rivaroxaban is an oral anticoagulant widely used for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). During long-term anticoagulant therapy, delayed or missed doses are ...Keywords
Funding Information
- funded
This publication has 48 references indexed in Scilit:
- Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non‐valvular atrial fibrillation: Results from ROCKET AFThe Journal of Clinical Pharmacology, 2014
- Clinical Pharmacokinetic and Pharmacodynamic Profile of RivaroxabanClinical Pharmacokinetics, 2013
- Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and HaemostasisJournal of Thrombosis and Haemostasis, 2013
- The effect of poor compliance on the pharmacokinetics of carbamazepine and its epoxide metabolite using Monte Carlo simulationActa Pharmacologica Sinica, 2012
- Management of antipsychotic treatment discontinuation and interruptions using model-based simulationsClinical Pharmacology: Advances and Applications, 2012
- Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationThe New England Journal of Medicine, 2011
- Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairmentEuropean Heart Journal, 2011
- The discovery and development of rivaroxabanAnnals of the New York Academy of Sciences, 2011
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976